Virtual Investor Event

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, headquartered in Cambridge, Mass.

An overhead view of glass laboratory vials and medical instruments neatly arranged on a white surface with soft natural lighting.
Cullinan Therapeutics Investor Event and REZILIENT3 Data

The company is hosting a virtual event for analysts and institutional investors today at 8:00 a.m. ET.

Nadim Ahmed, Chief Executive Officer, is a participant in the virtual event.

The webcast can be accessed at https://investors.cullinantherapeutics.com/events.

A replay will be archived on the website following the event.

Highlights

  • Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is hosting a virtual event for analysts and institutional investors today at 8:00 a.m. ET.
  • Nadim Ahmed, Chief Executive Officer, is a participant in the virtual event.
  • A replay will be archived on the website following the event.
  • The REZILIENT3 trial is a Phase 3 study evaluating zipalertinib plus chemotherapy.
  • REZILIENT3 trial data will be presented at Presidential Symposium 2 at the International Association for the Study of Lung Cancer's (IASLC) 2026 World Conference on Lung Cancer (WCLC).

REZILIENT3 Trial Data

The REZILIENT3 trial is a Phase 3 study evaluating zipalertinib plus chemotherapy.

REZILIENT3 trial data will be presented at Presidential Symposium 2 at the International Association for the Study of Lung Cancer's (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Press Release Details

This press release was published on September 14, 2026.

Contacts

  • Media contact: Rose Weldon, +1 215.801.7644, Rweldon@cullinantx.com.
  • Investor contact: Nick Smith, +1 401.241.3516, Nsmith@cullinantx.com.